Align Technology Inc. (ALGN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Align Technology ( ALGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Align Technology rose 78 cents (2.4%) to $33.60 on average volume. Throughout the day, 1.2 million shares of Align Technology exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in a price between $32.60-$33.85 after having opened the day at $32.75 as compared to the previous trading day's close of $32.82. Other companies within the Health Care sector that increased today were: Peregrine Pharmaceuticals ( PPHM), up 26.7%, Bacterin International Holdings ( BONE), up 17.8%, Rexahn Pharmaceuticals ( RNN), up 16%, and Opexa Therapeutics ( OPXA), up 15.9%.

Align Technology, Inc. designs, manufactures, and markets the invisalign system for treating malocclusion or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Align Technology has a market cap of $2.68 billion and is part of the health services industry. The company has a P/E ratio of 30.2, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 38.6% year to date as of the close of trading on Monday. Currently there are nine analysts that rate Align Technology a buy, one analyst rates it a sell, and one rates it a hold.

TheStreet Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Catalyst Pharmaceutical Partners ( CPRX), down 19.6%, Senesco Technologies ( SNT), down 12%, Ampio Pharmaceuticals ( AMPE), down 9.6%, and Retractable Technologies ( RVP), down 9.2%, were all laggards within the health care sector with GlaxoSmithKline ( GSK) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing